The Spectranetics Corp

The Spectranetics — Spectranetics — TCT 2016

13 slides from The Spectranetics's conference presentation, Nov 2, 2016

  1. Slide 1: Top-tier outcomes in the most complex patient population studied in DCB IDE trials

    1 Top-tier outcomes in the most complex patient population studied in DCB IDE trials Stellarex November 2, 2016 Exhibit 99.3

  2. Slide 2: Safe Harbor

    2 Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. You can identify these statements because they do not rela

  3. Slide 3: No Compromise ILLUMENATE Series

    3 No Compromise ILLUMENATE Series “We no longer need to compromise on safety or efficacy to bring optimal treatment to our PAD patients.” - Dr. Prakash Krishnan, Mount Sinai Largest patient population studied in randomized, core-lab adjudicated DCB trials

  4. Slide 4: No Compromise ILLUMENATE Series

    4 No Compromise ILLUMENATE Series Leading the way in clinical science to provide Proven Treatment Algorithms

  5. Slide 5: Patency

    5 Patency

  6. Slide 6: Randomized DCB Data – Comprehensive View

    6 Randomized DCB Data – Comprehensive View 86.0% 87.5% 73.5% 26.5% 8.1% 17.6% 0.0% 15.0% 30.0% 0.0% 25.0% 50.0% 75.0% 100.0% ILLUMENATE RCT IN.PACT SFA LEVANT 2 Patency Rate Severe Ca++ “While three drug-coated balloons have been rigorously studied, only two warrant adoption due to clinical efficacy

  7. Slide 7: ILLUMENATE: The Most Complex Patient Group Studied in DCB IDE Trials

    7 -5% 5% 15% 25% 35% 45% Severe ca++ Female Diabetic Renal insufficiency ILLUMENATE EU RCT & Pivotal IN.PACT SFA LEVANT 2 ILLUMENATE: The Most Complex Patient Group Studied in DCB IDE Trials -5% 5% 15% 25% 35% 45% Severe ca++ Female Diabetic Renal insufficiency ILLUMENATE EU RCT & Pivotal IN.PACT SF

  8. Slide 8: ILLUMENATE Pivotal – Most Complex Patients

    8  More complex patients enrolled in ILLUMENATE Pivotal vs. EU RCT  EU RCT patients similar to IN.PACT SFA and LEVANT 2  US Pivotal maintains top-tier patency in challenging patients ILLUMENATE Pivotal – Most Complex Patients 89.0% 82.3% 0% 25% 50% 75% 100% EU RCT N=222 US Pivotal N=200 37% 9% 13

  9. Slide 9: Randomized Data - Comparable View

    9 (1) Renal insufficiency not reported, number represents renal failure Randomized Data - Comparable View N (subjects/lesion) 222/254 220/221 316/316 Severe Ca++ 12.7% 8.1% 10.4% Renal Insufficiency 9.0% 8.3% 3.5% Diabetes 37.4% 40.5% 43.4% Pri m ar y Pa ten cy ( K M ) (1) 89.0% 87.5% 73.5% 0% 25% 5

  10. Slide 10: Safety Evidence

    10 Safety Evidence

  11. Slide 11: ILLUMENATE Safety Evidence

    11 ILLUMENATE Safety Evidence • ILLUMENATE EU RCT: statistical superiority for safety vs. POBA • ILLUMENATE Pivotal: statistical superiority for safety in challenging lesions vs. POBA Ex ac t C D -TL R r at es 5.2% 7.9% 4.6% 12.3% 0% 5% 10% 15% ILLUMENATE EU RCT Stellarex ILLUMENATE US Pivotal Stell

  12. Slide 12: ILLUMENATE RCTs No Compromise

    12 ILLUMENATE RCTs No Compromise Top-tier patency • Most complex patients Top-tier safety evidence • Single-digit CD-TLR • Statistical superiority to PTA PMA submission on-track Low drug dose • 2 µg/mm2 of paclitaxel

  13. Slide 13: Principal Investigators

    13  Dr. Prakash Krishnan Dr. Prakash Krishnan of Icahn School of Medicine at Mount Sinai has a dual academic appointment as Associate Professor of Medicine - Cardiology and Radiology. He also serves as the Director of Endovascular Interventions at The Mount Sinai Hospital's Cardiac Catheterization

Spectranetics — TCT 2016 on 6ix